–Higher CHI3L1 and CXCL13 in MS vs. control–Lower CCL2, BAFF, and APRIL in RMS vs. others–High CSF biomarkers (CHI3L1, CXCL10, CXCL12, and CXCL13) are associated with CDMS risk. Here, CCL2 is linked to myeloid sarcoma.